Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
20. Februar 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit
28. November 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Three Upcoming Investor Conferences
30. Oktober 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Two Upcoming Investor Conferences
23. Mai 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports First Quarter 2023 Financial Results
10. Mai 2023 16:03 ET
|
Kura Oncology, Inc.
– Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – – Site activation and enrollment in Phase 2 registration-directed trial of ziftomenib in NPM1-mutant AML...
Kura Oncology to Participate in JMP Securities Life Sciences Conference
09. Mai 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology to Report First Quarter 2023 Financial Results
03. Mai 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology to Participate in Upcoming Investor Conferences
01. März 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
23. Februar 2023 16:03 ET
|
Kura Oncology, Inc.
– Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose – – Multiple patients dosed in registration-directed trial of...
Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results
16. Februar 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...